Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis

Abstract Objective To evaluate the effects of hepatitis B vaccine and immunoglobulin in newborn infants of mothers positive for hepatitis B surface antigen. Design Systematic review and meta-analysis of randomised clinical trials. Data sources Electronic databases and hand searches. Review methods Randomised clinical trials were assessed for methodological quality. Meta-analysis was undertaken on three outcomes: the relative risks of hepatitis B occurrence, antibody levels to hepatitis B surface antigen, and adverse events. Results 29 randomised clinical trials were identified, five of which were considered high quality. Only three trials reported inclusion of mothers negative for hepatitis B e antigen. Compared with placebo or no intervention, vaccination reduced the occurrence of hepatitis B (relative risk 0.28, 95% confidence interval 0.20 to 0.40; four trials). No significant difference in hepatitis B occurrence was found between recombinant vaccine and plasma derived vaccine (1.00, 0.71 to 1.42; four trials) and between high dose versus low dose vaccine (plasma derived vaccine 0.97, 0.55 to 1.68, three trials; recombinant vaccine 0.78, 0.31 to 1.94, one trial). Compared with placebo or no intervention, hepatitis B immunoglobulin or the combination of plasma derived vaccine and hepatitis B immunoglobulin reduced hepatitis B occurrence (immunoglobulin 0.50, 0.41 to 0.60, one trial; vaccine and immunoglobulin 0.08, 0.03 to 0.17, three trials). Compared with vaccine alone, vaccine plus hepatitis B immunoglobulin reduced hepatitis B occurrence (0.54, 0.41 to 0.73; 10 trials). Hepatitis B vaccine and hepatitis B immunoglobulin seem safe, but few trials reported adverse events. Conclusion Hepatitis B vaccine, hepatitis B immunoglobulin, and vaccine plus immunoglobulin prevent hepatitis B occurrence in newborn infants of mothers positive for hepatitis B surface antigen.

[1]  L. Gallagher.  Hepatitis B. , 2016, Journal.

[2]  F. Hsieh,et al.  Efficacy of Hepatitis B Immune Globulin for Prevention of Perinatal Transmission of the Hepatitis B Virus Carrier State: Final Report of a Randomized Double‐Blind, Placebo‐Controlled Trial , 2007, Hepatology.

[3]  C. Gluud,et al.  Vaccines for preventing hepatitis B in health-care workers. , 2005, The Cochrane database of systematic reviews.

[4]  N. Wilson,et al.  Preventing and treating hepatitis B infection , 2005, BMJ : British Medical Journal.

[5]  S. Taback,et al.  Hepatitis B vaccination for patients with chronic renal failure. , 2004, The Cochrane database of systematic reviews.

[6]  I. Macgregor.  Screening assays for Transmissible Spongiform Encephalopathies (TSEs) , 2004, Vox sanguinis.

[7]  J. Brok,et al.  Hepatitis B prophylaxis for newborns of hepatitis B surface antigen‐positive mothers , 2004 .

[8]  R. Davis,et al.  Risk of anaphylaxis after vaccination of children and adolescents. , 2003, Pediatrics.

[9]  F. Song,et al.  Evaluating non-randomised intervention studies. , 2003, Health technology assessment.

[10]  L. Zou,et al.  Interruption of HBV intrauterine transmission: a clinical study. , 2003, World journal of gastroenterology.

[11]  Mei-Hwei Chang,et al.  Role of hepatitis B immunoglobulin in infants born to hepatitis B e antigen-negative carrier mothers in Taiwan , 2003, The Pediatric infectious disease journal.

[12]  Douglas G Altman,et al.  Interaction revisited: the difference between two estimates , 2003, BMJ : British Medical Journal.

[13]  S. Lolekha,et al.  Protective efficacy of hepatitis B vaccine without HBIG in infants of HBeAg-positive carrier mothers in Thailand. , 2002, Vaccine.

[14]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[15]  Z. Janowicz,et al.  Comparative efficacy, safety and immunogenicity of Hepavax-Gene and Engerix-B, recombinant hepatitis B vaccines, in infants born to HBsAg and HBeAg positive mothers in Vietnam: an assessment at 2 years. , 2002, Vaccine.

[16]  J. van Hattum,et al.  Characterization of a human monoclonal antibody obtained after immunization with plasma vaccine and a booster with recombinant‐DNA hepatitis B vaccine , 2002, Journal of medical virology.

[17]  A. Lok,et al.  World‐wide epidemiology of HBeAg‐negative chronic hepatitis B and associated precore and core promoter variants , 2002, Journal of viral hepatitis.

[18]  Christian Gluud,et al.  Reported Methodologic Quality and Discrepancies between Large and Small Randomized Trials in Meta-Analyses , 2001, Annals of Internal Medicine.

[19]  M. Kojouharova,et al.  Safety and Immunogenicity of a Yeast-Derived Recombinant Hepatitis B Vaccine in Bulgarian Newborns , 2001, Infection.

[20]  E. Lewis,et al.  Safety of neonatal hepatitis B vaccine administration. , 2001, The Pediatric infectious disease journal.

[21]  A. Harris,et al.  An economic evaluation of universal infant vaccination against hepatitis B virus using a combination vaccine (Hib‐HepB): a decision analytic approach to cost effectiveness , 2001, Australian and New Zealand journal of public health.

[22]  J. Ioannidis,et al.  Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. , 2001, JAMA.

[23]  M. Braun,et al.  Hypotonic–Hyporesponsive Episodes Reported to the Vaccine Adverse Event Reporting System (VAERS), 1996–1998 , 2000, Pediatrics.

[24]  Pauline R. Martin,et al.  The oxford textbook of clinical hepatology , 2000, Gastroenterology.

[25]  S. Ellenberg,et al.  Neonatal deaths after hepatitis B vaccine: the vaccine adverse event reporting system, 1991-1998. , 1999, Archives of pediatrics & adolescent medicine.

[26]  S. Hollis,et al.  What is meant by intention to treat analysis? Survey of published randomised controlled trials , 1999, BMJ.

[27]  S. Assad,et al.  Over a decade of experience with a yeast recombinant hepatitis B vaccine. , 1999, Vaccine.

[28]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[29]  Y. Poovorawan,et al.  Long term hepatitis B vaccine in infants born to hepatitis B e antigen positive mothers , 1997, Archives of disease in childhood. Fetal and neonatal edition.

[30]  T. Anil,et al.  Routine Prenatal Screening of Indian Women for HBsAg: Benefits Derived versus Cost , 1997, Tropical doctor.

[31]  S. Duan,et al.  A preliminary study on interruption of HBV transmission in uterus. , 1997, Chinese medical journal.

[32]  S. Ellenberg,et al.  Recombinant hepatitis B vaccination of neonates and infants: emerging safety data from the Vaccine Adverse Event Reporting System. , 1996, The Pediatric Infectious Disease Journal.

[33]  A. Walker,et al.  Japanese and American reports of randomized trials: differences in the reporting of adverse effects. , 1996, Controlled clinical trials.

[34]  V. Anan’ev,et al.  [The vaccinal prophylaxis of hepatitis B among children born to mothers with persistent HBs-antigenemia]. , 1996, Zhurnal mikrobiologii, epidemiologii, i immunobiologii.

[35]  Ruth E. Brown,et al.  Prevention of hepatitis B virus transmission by immunization. An economic analysis of current recommendations. , 1995, JAMA.

[36]  X. Shen,et al.  [Study on the efficacy of genetically engineered vaccines against hepatitis B for interruption of perinatal transmission]. , 1995, Zhonghua hu li za zhi = Chinese journal of nursing.

[37]  M. Chang,et al.  Long-term efficacy of recombinant hepatitis B vaccine and risk of natural infection in infants born to mothers with hepatitis B e antigen. , 1995, The Journal of pediatrics.

[38]  Z. G. Liu,et al.  [Cost-benefit analysis on immunization of newborns with hepatitis B vaccine in Jinan City]. , 1995, Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi.

[39]  A. Alver,et al.  Results of vaccinated infants born to HBsAg-positive mothers with different hepatitis B vaccines and doses. , 1995, The Turkish journal of pediatrics.

[40]  R. J. Hayes,et al.  Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. , 1995, JAMA.

[41]  S. Duan,et al.  Long-term immunogenicity and efficacy of recombinant yeast derived hepatitis B vaccine for interruption of mother-infant transmission of hepatitis B virus. , 1994, Chinese medical journal.

[42]  C. Begg,et al.  Operating characteristics of a rank correlation test for publication bias. , 1994, Biometrics.

[43]  Philip K. Bock.  Ethical Approval Not Required , 1994 .

[44]  G. D. de Gast,et al.  Passive-active immunization in infants of hepatitis Be antigen-positive mothers. Comparison of the efficacy of early and delayed active immunization. , 1993, American journal of diseases of children.

[45]  G. Carrin,et al.  Cost-effectiveness analysis of prenatal screening and vaccination against hepatitis B virus--the case of Belgium. , 1993, Social science & medicine.

[46]  V. Suvatte,et al.  Immunogenicity and efficacy of a recombinant DNA hepatitis B vaccine, GenHevac B Pasteur in high risk neonates, school children and healthy adults. , 1993, Asian Pacific journal of allergy and immunology.

[47]  H. Inskip,et al.  Cost-effectiveness of hepatitis B vaccine in The Gambia. , 1993, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[48]  B. Bloom,et al.  A Reappraisal of Hepatitis B Virus Vaccination Strategies Using Cost-Effectiveness Analysis , 1993, Annals of Internal Medicine.

[49]  N. Ganguly,et al.  Use of hepatitis B vaccine alone or in combination with hepatitis B immunoglobulin for immunoprophylaxis of perinatal hepatitis B infection. , 1992, Journal of tropical pediatrics.

[50]  Y. Poovorawan,et al.  Long term efficacy of hepatitis B vaccine in infants born to hepatitis B e antigen-positive mothers. , 1992, The Pediatric infectious disease journal.

[51]  N. Ganguly,et al.  Hepatitis B vaccine alone or in combination with anti-HBs immunoglobulin in the perinatal prophylaxis of babies born to HBsAg carrier mothers. , 1992, Acta virologica.

[52]  T. A. Chowdhury,et al.  Hepatitis B virus infection in pregnant mothers and its transmission to infants , 1992, Indian journal of pediatrics.

[53]  P. Corey,et al.  An efficacy trial of a mammalian cell-derived recombinant DNA hepatitis B vaccine in infants born to mothers positive for HBsAg, in Shanghai, China. , 1992, International journal of epidemiology.

[54]  Chin‐Yun Lee,et al.  The protective efficacy of recombinant hepatitis B vaccine in newborn infants of hepatitis B e antigen‐positive‐hepatitis B surface antigen carrier mothers , 1991, The Pediatric infectious disease journal.

[55]  P. Siripoonya,et al.  Prevention of hepatitis B infection in infants born to hepatitis B carrier mothers: low dosage vaccination , 1990, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[56]  H. Reesink,et al.  Hepatitis B Infection in Infants After Neonatal Immunization , 1989, Acta paediatrica Japonica : Overseas edition.

[57]  V. Suvatte,et al.  Hepatitis B immunization in high risk neonates born from HBsAg positive mothers: comparison between plasma derived and recombinant DNA vaccine. , 1989, Asian Pacific journal of allergy and immunology.

[58]  H. Reesink,et al.  PREVENTION OF HEPATITIS B VIRUS CARRIER STATE IN INFANTS ACCORDING TO MATERNAL SERUM LEVELS OF HBV DNA , 1989, The Lancet.

[59]  V. Suvatte,et al.  Hepatitis B immunization in high risk neonates born from HBsAg and HBeAg positive mothers: comparison of standard and low dose regimens. , 1988, Asian Pacific journal of allergy and immunology.

[60]  Liu Lh.  Comparative study of the efficacy of hepatitis B virus (HBV) vaccine combined with hepatitis B immunoglobulin(HBIG) versus vaccine alone in the interruption of the perinatal transmission of HBV carrier state , 1987 .

[61]  P. Siripoonya,et al.  A comparison between the efficacy of passive-active and active immunization for prevention of perinatal transmission of hepatitis B virus. , 1987, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[62]  D. Woodfield,et al.  A combination of hepatitis B vaccine and immunoglobulin does not protect all infants born to hepatitis B e antigen positive mothers. , 1987, The New Zealand medical journal.

[63]  A. Zuckerman,et al.  Dynamics and impact of perinatal transmission of hepatitis B virus in North India , 1987, Journal of medical virology.

[64]  K. Tan,et al.  Evaluation of a low dose of hepatitis B vaccine given within a childhood immunisation programme in Singapore. , 1986, The Journal of infection.

[65]  S. Hadler,et al.  Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. , 1986, The New England journal of medicine.

[66]  E. Yeoh,et al.  Efficacy and safety of recombinant hepatitis B vaccine in infants born to HBsAg-positive mothers. , 1986, The Journal of infection.

[67]  V. Suvatte,et al.  Efficacy of hepatitis-B immunoglobulin and hepatitis-B vaccine in prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg. , 1986, Asian Pacific journal of allergy and immunology.

[68]  H. Margolis,et al.  Prevention of perinatal acquisition of hepatitis B virus carriage using vaccine: preliminary report of a randomized, double-blind placebo-controlled and comparative trial. , 1985, Pediatrics.

[69]  R. Purcell,et al.  Prevention of hepatitis B virus carriage of infants using HBV vaccine in Shanghai. Preliminary report of a randomized double-blind placebo-controlled trial. , 1985, Chinese medical journal.

[70]  M. Piazza,et al.  HEPATITIS B IMMUNISATION WITH A REDUCED NUMBER OF DOSES IN NEWBORN BABIES AND CHILDREN , 1985, The Lancet.

[71]  P. Coursaget,et al.  Combined passive and active immunization for interruption of perinatal transmission of hepatitis B virus in Taiwan. , 1985, Hepato-gastroenterology.

[72]  L. Hwang,et al.  Hepatocellular Carcinoma and Hepatitis B Virus , 1984, Seminars in liver disease.

[73]  H. Reesink,et al.  PREVENTION OF THE HBsAg CARRIER STATE IN NEWBORN INFANTS OF MOTHERS WHO ARE CHRONIC CARRIERS OF HBsAg AND HBeAg BY ADMINISTRATION OF HEPATITIS-B VACCINE AND HEPATITIS-B IMMUNOGLOBULIN Double-blind Randomised Placebo-controlled study , 1984, The Lancet.

[74]  L. Hwang,et al.  PREVENTION OF PERINATALLY TRANSMITTED HEPATITIS B VIRUS INFECTIONS WITH HEPATITIS B IMMUNE GLOBULIN AND HEPATITIS B VACCINE , 1983, The Lancet.

[75]  村木 秀樹.  Hepatitis B Surface Antigen測定の改良法による再現性に関する検討 , 1983 .

[76]  L. Hwang,et al.  Postnatal infectivity of hepatitis B surface antigen-carrier mothers. , 1983, The Journal of infectious diseases.

[77]  W. Szmuness,et al.  A controlled clinical trial of the efficacy of the hepatitis B vaccine (heptavax B): A final report , 1981, Hepatology.

[78]  C E Stevens,et al.  The e antigen and vertical transmission of hepatitis B surface antigen. , 1977, American journal of epidemiology.

[79]  M. Imai,et al.  e antigen and anti-e in the serum of asymptomatic carrier mothers as indicators of positive and negative transmission of hepatitis B virus to their infants. , 1976, The New England journal of medicine.

[80]  R. Beasley,et al.  Vertical transmission of hepatitis B antigen in Taiwan. , 1975, The New England journal of medicine.

[81]  Dr. Chau Tai-Nin,et al.  Hepatocellular Carcinoma and Hepatitis B Virus , 2006 .

[82]  Ich Harmonised,et al.  INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE , 2006 .

[83]  L. Hirsch.  Competing interests: none declared. , 2006 .

[84]  M. Ramsay,et al.  Immunisation against infectious disease , 2006 .

[85]  M. Fisher,et al.  Adverse events associated with hepatitis B vaccine in U.S. children less than six years of age, 1993 and 1994. , 2001, Annals of epidemiology.

[86]  G. Da Villa,et al.  Immunization programme against hepatitis B virus infection in Italy: cost-effectiveness. , 1999, Vaccine.

[87]  N. Mcintyre,et al.  Oxford Textbook of Clinical Hepatology , 1999 .

[88]  J. Yao,et al.  Perinatal transmission of hepatitis B virus infection and vaccination in China. , 1996, Gut.

[89]  M. Chang,et al.  A follow-up study of combined vaccination with plasma-derived and recombinant hepatitis B vaccines in infants. , 1995, Vaccine.

[90]  H. Margolis,et al.  Long-Term Efficacy Of Active Postexposure Immunization Of Infants For Prevention Of Hepatitis B Virus Infection , 1995 .

[91]  H. Margolis,et al.  Long-term efficacy of active postexposure immunization of infants for prevention of hepatitis B virus infection. United States-People's Republic of China Study Group on Hepatitis B. , 1995, The Journal of infectious diseases.

[92]  J. B. Bravo González,et al.  [Field trial of the Cuban recombinant vaccine against hepatitis B (Heberbiovac HB). Study in newborn infants born to AgsHB+ mothers]. , 1992, Revista cubana de medicina tropical.

[93]  B. González,et al.  [Field trial of the Cuban recombinant vaccine against hepatitis B (Heberbiovac HB). Study in newborn infants born to AgsHB+ mothers]. , 1992 .

[94]  Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). , 1991, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[95]  Great Britain. Foreign Office.,et al.  Immunisation against infectious disease , 1988 .

[96]  L. H. Liu.  [Comparative study of the efficacy of hepatitis B virus (HBV) vaccine combined with hepatitis B immunoglobulin(HBIG) versus vaccine alone in the interruption of the perinatal transmission of HBV carrier state]. , 1987, Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi.

[97]  R. Paul,et al.  Efficacy of hepatitis B immune globulin in prevention of perinatal transmission of the hepatitis B virus. , 1984, Gastroenterology.

[98]  F. Hsieh,et al.  HBIG prophylaxis for perinatal HBV infections--final report of the Taiwan trial. , 1983, Developments in biological standardization.

[99]  P. Coursaget,et al.  Prevention of hepatitis B virus infection in children born to HBsAg positive/HBeAg positive mothers. Preliminary results of active and passive-active immunization. , 1983, Developments in biological standardization.